Status:

COMPLETED

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Lead Sponsor:

Novartis

Conditions:

Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.

Eligibility Criteria

Inclusion

  • Male or female
  • 18 years of age or older
  • msDBP and msSBP requirements:
  • 3A:
  • Diagnosis of moderate to severe hypertension (msSBP ≥ 160 mmHg and \< 200 mmHg, and/or msDBP ≥ 100 mmHg and \< 120 mmHg) at Visits 4, 5 or 6 (Qualifying BP visit)
  • In addition, at the visit immediately prior to the above qualifying visit, patients were also to have msSBP ≥ 145 mmHg and \< 200 mmHg and msDBP ≥ 95 mmHg and \< 120 mmHg) at Visits 3, 5 or 5.
  • Patients had to meet the above two sets of requirements at subsequent adjacent visits, i.e. either Visits 3 and 4, Visits 4 and 5, or Visits 5 and 6.
  • OR
  • 3B:
  • msSBP ≥ 180 mmHg and \< 200 mmHg with msDBP ≥ 95 mmHg and \< 120 mmHg, or msDBP ≥ 110 mmHg and \< 120 mmHg with msSBP ≥ 150 mmHg and \< 200 mmHg after at least one week of treatment with placebo (Visit 3 and on).

Exclusion

  • Continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start
  • Patients with an msSBP ≥ 200 mmHg or msDBP ≥ 120 mmHg at any time during the placebo run-in period were to be discontinued from the study.
  • Extremely elevated (defined) blood pressure at any point during the study
  • Pregnant or lactating women
  • Pre-menopausal women not taking accepted form of birth control
  • History or evidence of secondary form of hypertension
  • History of cardiovascular conditions
  • Other protocol-defined inclusion/exclusion criteria applied to the study.

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2009

Estimated Enrollment :

1191 Patients enrolled

Trial Details

Trial ID

NCT00765674

Start Date

September 1 2008

End Date

August 1 2009

Last Update

May 9 2011

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Investigative Site

Denver, Colorado, United States

2

Investigative Site

Sydney, Australia

3

Investigative Site

Ottawa, Canada

4

Investigative Site

Copenhagen, Denmark

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension | DecenTrialz